Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Academia and industry: allocating credit for discovery and development of new therapies
Jeffrey S. Flier
Jeffrey S. Flier
Published May 20, 2019
Citation Information: J Clin Invest. 2019;129(6):2172-2174. https://doi.org/10.1172/JCI129122.
View: Text | PDF
Viewpoint Article has an altmetric score of 143

Academia and industry: allocating credit for discovery and development of new therapies

  • Text
  • PDF
Abstract

Authors

Jeffrey S. Flier

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2010 Total
Citations: 2 2 1 2 4 2 1 14
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (14)

Title and authors Publication Year
Drug repurposing in amyotrophic lateral sclerosis (ALS)
Carroll E, Scaber J, Huber KV, Brennan PE, Thompson AG, Turner MR, Talbot K
Expert Opinion on Drug Discovery 2025
How to respond when biomedical science and global health is under existential threat.
Altmann DM, Rasmussen AL
Nature reviews. Immunology 2025
The fate of drug discovery in academia; dumping in the publication landfill?
Saqib U, Demaree IS, Obukhov AG, Baig MS, Ariel A, Hajela K
Oncotarget 2024
Funding multinational investigator-initiated clinical studies in Europe: why and how?
Del Álamo M, Lémeret S, Nieto C, Pandya L, Hagen H, Walker S, Demotes J
Trials 2024
Provenance and Clinical Benefit of Medicines Introduced to the French Market, 2008 to 2018.
Osipenko L, Potey P, Perez B, Kupryjanczuk A, Angelov F, Schuster A, Mossialos E
JAMA internal medicine 2023
Handbook of Research on Updating and Innovating Health Professions Education: Post-Pandemic Perspectives
CR Ford, KB Garza
2022
Demystifying Supervised Learning in Healthcare 4.0: A New Reality of Transforming Diagnostic Medicine.
Roy S, Meena T, Lim SJ
2022
Tackling the reproducibility problem to empower translation of preclinical academic drug discovery: is there an answer?
DR Janero
Expert Opinion on Drug Discovery 2021
Non-hydroxamate inhibitors of 1-deoxy-d-xylulose 5-phosphate reductoisomerase (DXR): A critical review and future perspective
S Kesharwani, S Sundriyal
European Journal of Medicinal Chemistry 2021
An urgent call to raise the bar in oncology
JJ Schnog, MJ Samson, RO Gans, AJ Duits
British Journal of Cancer 2021
Transformative dynamism in pharmaceutical and biomedical research: Complexity of integration of innovative R & D hubs
Y Omidi, H Omidian
Bioimpacts 2021
The Resurrection of Phenotypic Drug Discovery
WE Childers, KM Elokely, M Abou-Gharbia
ACS Medicinal Chemistry Letters 2020
Public research funding and pharmaceutical prices: do Americans pay twice for drugs?
RM Conti, FS David
F1000Research 2020
Burger's Medicinal Chemistry and Drug Discovery
S Bruno, L Ronda, S Faggiano, S Bettati, A Mozzarelli
Burger's Medicinal Chemistry and Drug Discovery 2010

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 7 news outlets
Blogged by 2
Referenced in 1 policy sources
Posted by 111 X users
On 3 Facebook pages
73 readers on Mendeley
See more details